Multisystem Processes & Disorders

Vancomycin-resistant enterococcus: management and infection control

Clinical Overview and When to Suspect VRE

— Bacteremia / catheter-related bloodstream infection (most common serious presentation)

— Complicated UTI (often catheter-associated; asymptomatic bacteriuria usually does NOT need treatment)

— Intra-abdominal/pelvic abscess (post-op, biliary, peritoneal dialysis)

— Endocarditis (subacute, prosthetic or native valve)

— Surgical site infection, decubitus ulcer superinfection

— Rarely meningitis (post-neurosurgical, shunt)

— Hospitalized >72 h, especially ICU, hematology/oncology, transplant, or hemodialysis patient with new fever or positive blood culture growing gram-positive cocci in chains/pairs

— Recent broad-spectrum antibiotic exposure (vancomycin, 3rd-gen cephalosporins, anti-anaerobics like metronidazole/pip-tazo, fluoroquinolones)

— Prior VRE colonization on surveillance swab, prior C. difficile, long LTAC/SNF stay

— Indwelling devices: central line, urinary catheter, biliary stent

— Liver transplant recipients (highest-risk solid organ transplant group)

— Enterococci = #2 cause of healthcare-associated infections in US ICUs

— ~80% of E. faecium isolates in US hospitals are vancomycin-resistant; <10% of E. faecalis

— Colonization typically precedes infection by days–weeks; GI tract is the reservoir

Vancomycin-resistant enterococcus (VRE) = Enterococcus faecium (>90% of US VRE) or E. faecalis with acquired resistance to vancomycin via vanA (high-level, inducible) or vanB (variable) gene clusters altering peptidoglycan precursor (D-Ala-D-Lac instead of D-Ala-D-Ala).

Clinical syndromes caused by VRE:

When to suspect VRE on Step 3:

Epidemiology pearls:

Board pearl: A neutropenic leukemia patient on prolonged pip-tazo who spikes a fever with GPCs in chains on blood culture → think VRE faecium bacteremia until proven otherwise, and empirically cover with daptomycin or linezolid, NOT vancomycin.

Presentation Patterns and Key History

— Inpatient day 7–14 on broad-spectrum antibiotics develops new fever, leukocytosis, or hemodynamic drift

— Post-liver transplant patient with biliary leak and ascending cholangitis

— Hemodialysis patient with tunneled catheter, recurrent gram-positive bacteremia

— Nursing home transfer with chronic indwelling Foley, now febrile and confused

— Post-op colorectal patient with intra-abdominal abscess despite pip-tazo

— Antibiotic exposure in prior 90 days — vancomycin, cephalosporins, carbapenems, FQ, anti-anaerobics all select for VRE

— Healthcare exposures: prior hospitalization, LTAC, SNF, dialysis unit

— Prior MDRO colonization (VRE, MRSA, CRE, ESBL) — check surveillance and prior cultures

— Devices: CVC, PICC, Foley, biliary stent, PEG, LVAD, prosthetic valve/joint

— Immunosuppression: chemo, neutropenia, transplant, high-dose steroids, biologics

— Recent GI/GU surgery or instrumentation (ERCP, colonoscopy with polypectomy, TURP)

— Bacteremia: fever, rigors often less dramatic than S. aureus; can be indolent

— UTI: dysuria, suprapubic pain, flank pain if pyelonephritis; in catheterized/elderly may present only as delirium or hypotension

— Intra-abdominal: persistent fever despite source control, recurrent abscess

— Endocarditis: subacute weight loss, night sweats, embolic phenomena, new murmur — enterococcus is the 3rd most common IE pathogen

Typical Step 3 vignette anchors:

Critical history elements to extract:

Symptom patterns by site:

Key distinction: Enterococcal colonization vs infection — a positive rectal/perirectal surveillance swab or growth from a non-sterile site (wound, sputum, drain) without clinical signs is colonization and should NOT trigger systemic antibiotics. Only treat when there is a compatible syndrome and culture from a sterile site or symptomatic UTI.

Board pearl: Enterococcal bacteremia without an obvious source mandates TTE, and TEE if persistent or prosthetic valve/device — IE prevalence in E. faecalis bacteremia approaches 25%.

Physical Exam Findings and Hemodynamic Assessment

— Fever (often low-grade in elderly/immunocompromised; may be absent)

— Tachycardia, widened pulse pressure, hypotension if septic

— qSOFA ≥2 (RR ≥22, SBP ≤100, altered mentation) → escalate workup and start sepsis bundle

— Central line / PICC site: erythema, tenderness, purulence, tunnel cord — suggests catheter-related BSI

— Cardiac: new or changing murmur (often regurgitant), peripheral stigmata of IE (Janeway lesions, Osler nodes, splinter hemorrhages, Roth spots) — uncommon but highly specific

— Abdomen: RUQ tenderness + jaundice → cholangitis (Charcot triad); rebound/guarding → peritonitis; palpable mass or persistent ileus → abscess

— GU: CVA tenderness, suprapubic tenderness; in men assess prostate (avoid vigorous massage in suspected prostatitis with bacteremia risk)

— Skin/wounds: decubitus ulcers, surgical incisions — probe for depth, undermining, purulence

— Joints: effusion, warmth — prosthetic joint infection consideration

— Lactate, MAP, urine output, capillary refill, mottling score

— Septic shock criteria: vasopressor requirement to MAP ≥65 + lactate >2 despite resuscitation

— Catheter dwell time, exit site, ease of blood draw

— Foley: tenderness on palpation, sediment, purulent drainage around catheter

General appearance and vitals:

Site-directed exam:

Hemodynamic assessment for sepsis:

Device evaluation:

CCS pearl: In a CCS case with suspected VRE bacteremia, on initial exam order vital signs q1–2h, examine line sites, obtain peripheral and line-drawn cultures (differential time-to-positivity), and place patient on contact precautions immediately — don't wait for culture confirmation. Advance clock only after these orders.

Board pearl: Differential time-to-positivity of ≥2 h (line culture positive ≥2 h before peripheral) supports catheter-related BSI and triggers line removal decision.

Diagnostic Workup — Initial Labs, Imaging, Cultures

— CBC with differential — leukocytosis, left shift, or neutropenia

— CMP — renal/hepatic function guides drug dosing (daptomycin, linezolid metabolism)

— Lactate, procalcitonin (trend), CRP

— Coags if septic or considering procedures

— Two sets of blood cultures from separate sites before antibiotics (one peripheral + one from each indwelling line if catheter-related BSI suspected)

— Urinalysis + urine culture (replace Foley before sampling if in >2 weeks)

— Site-specific cultures: wound, peritoneal fluid, bile, CSF as indicated

— Gram stain: gram-positive cocci in pairs and short chains

— Identification: MALDI-TOF or biochemical to distinguish E. faecium vs E. faecalis — species matters for therapy (faecium more often resistant; faecalis often retains ampicillin susceptibility)

— Susceptibilities: vancomycin MIC, ampicillin, daptomycin, linezolid, tigecycline, +/- ceftriaxone (for synergy in E. faecalis IE)

— Bacteremia of unknown source: TTE first, TEE if non-diagnostic, persistent bacteremia >72h, or prosthetic material

— Intra-abdominal: CT abdomen/pelvis with contrast for abscess, leak, ischemic bowel

— Spine/back pain + bacteremia: MRI spine for vertebral osteomyelitis/epidural abscess

— Joint: aspiration, MRI for prosthetic joint

— Peri-rectal or stool swab for VRE colonization in high-risk units (ICU, BMT) per institutional policy — informs cohorting and empiric coverage

Initial labs (order on every suspected VRE infection):

Microbiology workflow:

Imaging by syndrome:

Surveillance cultures:

Step 3 management: Repeat blood cultures every 48 h until clearance in VRE bacteremia — persistent positivity >72 h on appropriate therapy is the trigger for TEE, source control reassessment, and consideration of combination therapy (e.g., daptomycin + ampicillin or ceftaroline).

Board pearl: Asymptomatic VRE bacteriuria in a catheterized patient → do not treat; change/remove catheter and reassess. Exceptions: pregnancy, pre-urologic procedure with mucosal trauma.

Diagnostic Workup — Advanced and Confirmatory Studies

— TTE on all patients with enterococcal bacteremia

— TEE indicated when: prosthetic valve, intracardiac device (PPM/ICD/LVAD), persistent bacteremia >72 h, community-acquired or unknown-source bacteremia, ≥3 of NOVA criteria (Number of cultures, Origin unknown, Valve disease, Auscultation of murmur)

— Modified Duke criteria applied; enterococcus = "typical organism" only when community-acquired without primary focus

— Confirm vancomycin MIC ≥32 µg/mL (resistant) vs intermediate (8–16)

— Daptomycin MIC — request explicit value; MIC ≤4 = susceptible, but in serious VRE infection target high-dose daptomycin (8–12 mg/kg) and consider susceptibility "susceptible-dose dependent" framing

— Linezolid resistance screening if prior exposure

— Ampicillin susceptibility for E. faecalis (still ~95% S) — ampicillin remains drug of choice for ampicillin-S enterococci even when vanco-R

— Repeat CT to track abscess response; IR drainage planning

— HIDA or MRCP if biliary source unclear

— Tagged WBC scan or FDG-PET for occult hardware infection

— PCR-based blood culture panels (e.g., BCID2) detect vanA/vanB within hours → enables earlier appropriate empiric therapy

— Whole-genome sequencing for outbreak investigation (epidemiologic, not clinical)

— Daily blood cultures until two consecutive negative sets

— Document time to clearance — prolonged bacteremia (>7 days) is independent mortality predictor

Echocardiography decision tree (enterococcal bacteremia):

Susceptibility nuances:

Source control imaging:

Molecular diagnostics:

Repeat surveillance:

CCS pearl: In the CCS interface, after first positive VRE blood culture, advance the clock 24 h and reorder blood cultures, repeat CBC/CMP, recheck source-control imaging, and order TTE; if TTE limited, order TEE. Missing these steps loses points even if antibiotics are correct.

Board pearl: E. faecalis + bacteremia + colon source → screen for occult colorectal malignancy with colonoscopy after recovery (similar to Streptococcus gallolyticus association, though weaker).

Risk Stratification and First-Line Management Logic

— Sterile-site infection (blood, CSF, joint, deep abscess) → IV bactericidal therapy

— Uncomplicated cystitis → oral agent (nitrofurantoin, fosfomycin, doxycycline) if susceptible

— Colonization → no antibiotics; infection control measures only

— E. faecalis, ampicillin-S (even if vanco-R) → ampicillin ± ceftriaxone or aminoglycoside synergy for IE

— E. faecium, vanco-R, ampicillin-R (typical VRE) → daptomycin or linezolid first-line

— Septic shock / neutropenic fever / endocarditis → high-dose daptomycin (10–12 mg/kg) + β-lactam (ampicillin or ceftaroline) for synergy; or linezolid if daptomycin not preferred (e.g., pulmonary source — daptomycin inactivated by surfactant)

— Stable bacteremia, line source removed → daptomycin 8–10 mg/kg or linezolid 600 mg q12h

— UTI: nitrofurantoin (cystitis only), fosfomycin (single dose for cystitis), or IV daptomycin/linezolid for pyelonephritis (note: daptomycin renally excreted, concentrates in urine)

— Remove infected CVC/PICC in catheter-related VRE bacteremia (strong IDSA recommendation)

— Drain abscesses, debride necrotic tissue, exchange biliary stents

— Remove infected hardware when feasible

— Uncomplicated bacteremia with source control: 14 days from first negative culture

— Endocarditis: 6 weeks

— Osteomyelitis: 6–8 weeks

— Cystitis: 5–7 days

Determine syndrome severity and source before choosing drug:

Species and resistance pattern dictate drug:

Severity stratification:

Source control is non-negotiable:

Duration framework:

Step 3 management: Always pair antimicrobial selection with (1) source control, (2) repeat blood cultures q48h, (3) TTE, (4) contact precautions, (5) antibiotic stewardship — narrow once susceptibilities return.

Board pearl: Linezolid is bacteriostatic against enterococcus; in endocarditis or neutropenia where bactericidal activity matters, daptomycin is preferred, often with a synergistic β-lactam.

Pharmacotherapy — First-Line Drug Regimens

— Dose: 8–12 mg/kg IV q24h for serious VRE infection (FDA label 6 mg/kg is inadequate for VRE bacteremia/IE)

— Renal dosing: q48h if CrCl <30 or HD

— Monitor CPK weekly; hold if CPK >5× ULN or symptomatic myopathy; avoid concurrent statins when feasible

— Do not use for pneumonia — inactivated by pulmonary surfactant

— Eosinophilic pneumonia is a rare but classic adverse effect (1–4 weeks in)

— Dose: 600 mg IV/PO q12h (100% oral bioavailability — useful for step-down)

— No renal adjustment; metabolized non-enzymatically

— Toxicities: thrombocytopenia (dose- and duration-dependent, >2 weeks), peripheral and optic neuropathy (>4 weeks), serotonin syndrome with SSRIs/MAOIs/linezolid (weak MAOI), lactic acidosis, myelosuppression

— Monitor CBC weekly

— Preferred when daptomycin contraindicated, pulmonary source, or oral step-down desired

— Daptomycin + ampicillin or ceftaroline → ampicillin/ceftaroline alters surface charge, enhances daptomycin binding even in ampicillin-R E. faecium

— Consider for persistent bacteremia >72h or daptomycin MIC ≥3

— Quinupristin-dalfopristin — E. faecium only (no faecalis activity), arthralgia/myalgia common

— Tigecycline — bacteriostatic, low serum levels (avoid bacteremia), useful for intra-abdominal

— Oritavancin, dalbavancin — long-acting lipoglycopeptides, limited VRE data (variable vs vanA)

— Nitrofurantoin 100 mg PO BID × 5 d (cystitis, CrCl >30)

— Fosfomycin 3 g PO × 1 (cystitis)

— Doxycycline if susceptible

Daptomycin (lipopeptide, bactericidal):

Linezolid (oxazolidinone, bacteriostatic):

Tedizolid: newer oxazolidinone, less myelosuppression, but FDA-approved only for ABSSSI; off-label for VRE

Combination therapy (severe/persistent infection):

Alternative/salvage agents:

UTI-specific agents:

Board pearl: Daptomycin + ceftaroline is the go-to salvage for persistent VRE bacteremia failing monotherapy — synergy without ampicillin susceptibility requirement.

Source Control, Line Management, and Endocarditis Therapy

— Remove non-tunneled CVCs and PICCs promptly — short-term lines, low salvage value

— Tunneled catheters/ports: remove if tunnel infection, septic shock, persistent bacteremia >72h, endocarditis, or metastatic infection; salvage attempt acceptable for uncomplicated short-duration bacteremia in patients with limited access (e.g., dialysis), using antibiotic lock therapy + systemic Rx

— Antibiotic lock options for VRE: daptomycin or linezolid + heparin

— E. faecalis (ampicillin-S, even vanco-R): ampicillin 2 g IV q4h + ceftriaxone 2 g IV q12h × 6 weeks (preferred; avoids aminoglycoside nephrotoxicity)

— E. faecium, VRE: daptomycin 10–12 mg/kg + ampicillin or ceftaroline × 6 weeks; linezolid is alternative

— Surgical indications (same as other IE): heart failure, perivalvular abscess, recurrent emboli on appropriate therapy, large vegetation >10 mm with embolic event, persistent bacteremia despite source control

— Prosthetic valve IE: longer course (≥6 weeks), early surgical consultation

— Percutaneous drainage by IR when abscess ≥3–4 cm or symptomatic

— Surgical washout for diffuse peritonitis, anastomotic leak, ischemic bowel

— Biliary: ERCP for obstruction, stent exchange in cholangitis

— Remove or exchange long-dwell Foley before culture and treatment

— Relieve obstruction (stones, BPH, stricture) — nephrostomy or stent if hydronephrosis

— Pacemaker/ICD: complete system removal (leads + generator) per HRS guidelines

— Prosthetic joint: two-stage exchange standard; DAIR (debridement, antibiotics, implant retention) only if early, well-fixed, susceptible organism — rarely chosen for VRE

Catheter management in VRE bacteremia:

Endocarditis management:

Intra-abdominal source:

Urinary source:

Hardware infections:

CCS pearl: Order "remove central venous catheter" as a discrete action in CCS for catheter-related VRE bacteremia; failure to do so caps the score even with correct antibiotics. Then order new peripheral IV access and repeat blood cultures 48 h after removal.

Special Populations — Elderly and Renal/Hepatic Impairment

— Atypical presentation: delirium, falls, anorexia, hypothermia rather than fever

— Polypharmacy increases risk of linezolid–SSRI serotonin syndrome and daptomycin–statin myopathy

— Lower physiologic reserve → earlier escalation, lower threshold for ICU

— Goals-of-care discussion early, especially with recurrent MDRO infections or LTAC-dependent course

— Daptomycin: CrCl ≥30 → q24h; CrCl <30 or HD → q48h (dose after dialysis on HD days)

— Linezolid: no dosage adjustment for renal function, BUT metabolites accumulate in severe CKD (clinical significance uncertain); monitor for cytopenias

— Ampicillin: renally cleared, adjust q6–8h dosing

— Nitrofurantoin: avoid if CrCl <30 (inadequate urinary concentration, peripheral neuropathy risk)

— Fosfomycin: avoid if CrCl <30 (per label)

— Daptomycin and linezolid: no specific hepatic dose adjustment, but monitor LFTs

— Linezolid lactic acidosis risk increased in hepatic dysfunction

— Tigecycline: reduce dose in severe hepatic impairment (Child-Pugh C)

— VRE bacteremia in HD patients often catheter-related → aggressive line management

— Daptomycin: 6 mg/kg post-HD (some experts use 8–10 mg/kg post-HD for serious infection); confirm with local pharmacy

— Use AV fistula/graft preferentially to avoid recurrent catheter infections

— Drug interactions: linezolid–tacrolimus, daptomycin generally safe

— Higher mortality with VRE bacteremia; aggressive source control

Elderly considerations:

Renal impairment:

Hepatic impairment:

Hemodialysis-specific:

Solid organ transplant (especially liver):

Step 3 management: In an elderly nursing home resident with VRE bacteruria and no symptoms, do not treat with antibiotics; document colonization, continue contact precautions, address the catheter, and educate facility staff. Reflexive treatment drives resistance and C. difficile.

Board pearl: Hold statins during daptomycin therapy when feasible — synergistic rhabdomyolysis risk; if statin essential, monitor CPK ≥2×/week.

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— VRE infection in pregnancy is uncommon but high-stakes

— Ampicillin remains preferred for ampicillin-S enterococci (E. faecalis), pregnancy category B

— Daptomycin: category B, limited human data, considered acceptable for serious infection

— Linezolid: category C, animal data show fetal toxicity; use only when alternatives unsuitable

— Nitrofurantoin: avoid at term (38–42 weeks) and in G6PD deficiency — risk of neonatal hemolysis; acceptable in 2nd trimester for cystitis

— Fosfomycin: category B, acceptable single-dose for asymptomatic bacteriuria/cystitis

— Always treat asymptomatic bacteriuria in pregnancy (including VRE) — pyelonephritis prevention

— VRE most often in NICU (low birth weight, prolonged lines, broad-spectrum exposure) and pediatric oncology

— Linezolid: well-studied, 10 mg/kg q8h <12 years

— Daptomycin: approved for children ≥1 year; dosing weight- and age-dependent (higher mg/kg in younger children due to faster clearance)

— Avoid quinupristin-dalfopristin in young children (myalgia)

— VRE colonization screening informs empiric therapy

— If colonized + neutropenic fever + clinical instability → add daptomycin or linezolid to standard pip-tazo or cefepime regimen empirically

— Do NOT routinely add anti-VRE coverage for every neutropenic fever — only when colonized or unstable

— Liver transplant recipients have highest VRE incidence; pre-transplant colonization predicts post-transplant infection

— Some centers perform pre-transplant decolonization (unproven)

— Increased mortality compared to non-transplant; lower threshold for combination therapy

Pregnancy:

Pediatrics:

Neutropenic fever:

Transplant:

HIV/AIDS: not a primary VRE risk; consider concurrent opportunistic infections

Board pearl: Asymptomatic bacteriuria is treated in only two scenarios — pregnancy and pre-urologic procedure with anticipated mucosal trauma. VRE bacteriuria follows the same rule.

Complications and Adverse Outcomes

— Persistent bacteremia (>72 h on therapy) — independent mortality predictor; triggers TEE, source-control reassessment, combination therapy

— Metastatic seeding: endocarditis, vertebral osteomyelitis, psoas abscess, septic arthritis, endophthalmitis

— Septic shock and multi-organ failure — mortality 30–50% in VRE bacteremia in some series

— Recurrent bacteremia — often from inadequate source control or unrecognized endovascular focus

— Daptomycin: myopathy/rhabdomyolysis (monitor CPK), eosinophilic pneumonia (cough, dyspnea, infiltrates, eosinophilia — stop drug, steroids), peripheral neuropathy (rare)

— Linezolid: thrombocytopenia (most common, reversible), anemia, neutropenia, peripheral and optic neuropathy with >28 days use, serotonin syndrome with serotonergic drugs, lactic acidosis (mitochondrial toxicity), hypoglycemia

— Quinupristin-dalfopristin: severe arthralgia/myalgia, infusion-site reactions (give via central line)

— Tigecycline: nausea/vomiting, pancreatitis, FDA black-box for increased mortality in serious infections

— Daptomycin non-susceptibility on therapy (especially with subtherapeutic dosing) — request repeat MIC for persistent bacteremia

— Linezolid resistance with prolonged use or prior exposure

— Cross-transmission to MRSA → VRSA (rare but reported)

— Prolonged length of stay (mean +2 weeks for VRE bacteremia)

— Discharge to LTAC/SNF more likely

— Cost: $25,000–$80,000 added per VRE infection episode

— C. difficile colitis risk amplified by therapy

Infection-related complications:

Treatment-related adverse events:

Resistance emergence:

Healthcare system complications:

Key distinction: Eosinophilic pneumonia from daptomycin typically appears 2–4 weeks into therapy with peripheral eosinophilia, bilateral infiltrates, and BAL eosinophils >25% — discontinue daptomycin and start systemic corticosteroids; do not mistake for treatment failure or hospital-acquired pneumonia.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Septic shock (vasopressors, lactate >2 despite fluids)

— Respiratory failure / mechanical ventilation

— Multi-organ dysfunction (AKI requiring CRRT, DIC, hepatic failure)

— Endocarditis with hemodynamic instability or large vegetation pending surgery

— Need for close monitoring after high-risk procedure (cardiac surgery, abscess drainage with sepsis)

— Infectious Diseases: mandatory for all VRE bacteremia and endocarditis — ID consult independently associated with reduced mortality in gram-positive bacteremia

— Cardiothoracic surgery: IE with surgical indications (HF, abscess, large vegetation, recurrent emboli, persistent infection)

— Cardiology: TEE, valve assessment, device extraction (electrophysiology for PPM/ICD removal)

— Interventional radiology: abscess drainage, biliary intervention

— Hepatology/transplant: in transplant recipients

— Antibiotic stewardship pharmacy: dosing optimization, TDM

— Stable bacteremia, line removed, source controlled → floor with telemetry if cardiac concern

— Persistent bacteremia, deteriorating vitals → step-down/ICU

— Community hospital lacking TEE, cardiac surgery, or transplant ID expertise → transfer for endocarditis with surgical indications

— Afebrile ≥48 h, hemodynamically stable, source controlled, negative blood cultures, oral or OPAT plan in place, follow-up arranged

ICU admission criteria:

Subspecialty consultation:

Floor vs step-down vs ICU decision:

Transfer to higher level of care:

CCS pearl: In a CCS septic VRE case, sequence: (1) ABCs and IV access, (2) blood cultures ×2, (3) lactate + sepsis labs, (4) empiric antibiotics within 1 hour, (5) 30 mL/kg crystalloid, (6) ICU transfer if hypotensive after fluids, (7) ID consult, (8) contact precautions, (9) source-control imaging. Missing the 1-hour antibiotic mark or ID consult drops score.

Discharge readiness:

Board pearl: OPAT (Outpatient Parenteral Antimicrobial Therapy) with daptomycin q24h or weekly dalbavancin is increasingly used for completion of VRE therapy — requires PICC, weekly labs, and ID follow-up.

Key Differentials — Other Gram-Positive Bacteremias

— Gram stain: gram-positive cocci in clusters (vs enterococcus in pairs/chains)

— More acute, virulent course; higher rate of metastatic complications

— Treatment: MSSA → nafcillin/cefazolin; MRSA → vancomycin or daptomycin

— Always get TTE/TEE; ID consult mandatory

— Common blood culture contaminant; significant if ≥2 sets positive, indwelling device, or compatible syndrome

— Often vancomycin-susceptible; prosthetic device infections common

— Subacute IE in patients with dental procedures or poor dentition

— Highly penicillin-susceptible typically

— IE + colorectal cancer association — colonoscopy mandatory

— Distinguish from enterococcus by bile esculin (both positive) + PYR (enterococcus positive, S. gallolyticus negative) and 6.5% NaCl growth (enterococcus yes, S. gallolyticus no)

— Bacteremia in elderly diabetics, postpartum women, neonates

— Penicillin-susceptible

— Gram-positive rod, not coccus — easy distinction on Gram stain

— Elderly, pregnant, immunocompromised; meningitis and bacteremia

— Ampicillin treatment; intrinsically resistant to cephalosporins

— Intrinsically vancomycin-resistant gram-positives that can mimic VRE on initial workup

— Identification by MALDI-TOF prevents misclassification

— Treat with ampicillin or clindamycin; usually not pathogenic except in immunocompromised

Staphylococcus aureus (MSSA/MRSA) bacteremia:

Coagulase-negative Staphylococcus (CoNS):

Viridans group streptococci:

Streptococcus gallolyticus (formerly S. bovis):

Group B Streptococcus (S. agalactiae):

Listeria monocytogenes:

Lactobacillus, Leuconostoc, Pediococcus:

Key distinction: Enterococcus vs S. gallolyticus — both bile-esculin positive, but enterococcus grows in 6.5% NaCl and is PYR-positive. Both prompt colonoscopy when associated with IE (gallolyticus stronger evidence, enterococcus weaker but reasonable in faecalis).

Board pearl: Gram-positive cocci in chains + bacteremia in a hospitalized patient on broad-spectrum antibiotics → VRE until proven otherwise.

Key Differentials — Non-Enterococcal Causes of Same Syndromes

— S. aureus (MRSA/MSSA), CoNS, Candida species, gram-negative rods (Klebsiella, Pseudomonas)

— Candida CRBSI: mandatory line removal, echinocandin therapy, ophthalmology exam for endophthalmitis

— E. coli (often ESBL), Klebsiella, Pseudomonas, Proteus, Candida

— Polymicrobial in chronic catheter

— Polymicrobial typical: E. coli, Bacteroides, Klebsiella, Enterococcus, anaerobes

— Empiric pip-tazo, carbapenem, or ceftriaxone + metronidazole; add anti-VRE coverage when colonized, post-transplant, severe nosocomial infection, or persistent fever

— S. aureus (most common overall, IVDU), viridans strep (subacute), HACEK organisms, fungal (prosthetic valve, IVDU), culture-negative (Bartonella, Coxiella, Tropheryma)

— Marantic (NBTE) in malignancy, Libman-Sacks in SLE — non-infective vegetations

— S. aureus most common; gram-negatives in elderly, neonates, IVDU; Neisseria gonorrhoeae in young sexually active adults

— Broad differential: occult abscess, endocarditis, vertebral osteo, urinary, biliary, C. difficile colitis with bacteremia, line infection

— Leuconostoc, Pediococcus, Lactobacillus — intrinsically vanco-R gram-positives, often misidentified initially

— Usually benign; treat only if clinically significant (immunocompromised, persistent positives)

Catheter-related bloodstream infection (CRBSI) alternatives:

Healthcare-associated UTI:

Intra-abdominal infection:

Endocarditis differentials:

Septic arthritis / osteomyelitis:

Sepsis without obvious source:

Pseudo-VRE:

Key distinction: A liver transplant patient with biliary leak and gram-positive cocci in chains: differential is VRE vs streptococci vs intrinsically vanco-R organisms. MALDI-TOF identification within 24 h and tailored therapy is the Step 3 expectation, rather than indefinite empiric broad coverage.

Board pearl: Empiric anti-VRE coverage in hospital-acquired intra-abdominal infection is recommended for post-liver-transplant patients, those with prior VRE colonization, or recipients of broad-spectrum antibiotics; routine addition is not warranted.

Infection Control, Secondary Prevention, and Long-Term Plan

— Contact precautions: gown + gloves on room entry, dedicated equipment (stethoscope, BP cuff), single room or cohort with other VRE patients

— Hand hygiene: soap and water OR alcohol-based hand rub (alcohol effective for VRE, unlike C. difficile)

— Environmental cleaning: daily and terminal disinfection with EPA-registered disinfectant; high-touch surfaces (bed rails, call buttons, toilets, commodes) emphasized

— Active surveillance in high-risk units (ICU, BMT, transplant) per institutional policy — peri-rectal swabs on admission and weekly

— Antibiotic stewardship: restrict vancomycin, 3rd-gen cephalosporins, anti-anaerobics; this is the most impactful long-term intervention

— Practice varies; many institutions discontinue after 3 consecutive negative weekly surveillance cultures off antibiotics, others maintain indefinitely during hospitalization

— Re-flag on readmission per institutional protocol

— No proven effective decolonization regimen for VRE (unlike MRSA mupirocin/CHG bathing)

— Chlorhexidine bathing in ICU may reduce transmission and bloodstream infections in colonized patients — adopted in many ICUs

— Notify receiving facility (SNF, LTAC, rehab) of VRE status

— Educate patient/family on hand hygiene and home precautions (home contact precautions generally not required for household members of healthy contacts)

— OPAT setup: PICC, weekly labs (CBC, CMP, CPK if daptomycin), ID follow-up

— Bacteremia: 14 d from first negative culture with source control

— Endocarditis: 6 weeks

— Document end date in discharge summary

Infection control measures (the Step 3 backbone for VRE):

Discontinuation of precautions:

Decolonization:

Discharge planning:

Antibiotic completion:

Step 3 management: The single highest-yield prevention intervention is antibiotic stewardship — reducing unnecessary vancomycin and broad-spectrum exposure cuts new VRE acquisition more than any infection control measure. Pair with hand hygiene compliance audits and chlorhexidine bathing in ICUs.

Follow-Up, Monitoring, and Counseling

— Daptomycin: weekly CPK; CBC, CMP weekly; hold statins; watch for new dyspnea/cough → consider eosinophilic pneumonia

— Linezolid: weekly CBC (thrombocytopenia by week 2); LFTs; lactate if metabolic acidosis; visual exam if >28 days (optic neuropathy); avoid serotonergic agents — coordinate with psychiatry if SSRI essential

— Repeat blood cultures: q48h until two consecutive negatives

— Daily ID rounds during admission

— ID clinic at 1–2 weeks post-discharge, then at end of antibiotic course

— OPAT nursing weekly home visit or infusion center labs

— PCP follow-up within 1–2 weeks for medication reconciliation, functional reassessment

— Echocardiogram repeat at end of therapy if endocarditis

— Document VRE colonization in chart for future admissions

— Re-evaluate device necessity (Foley, CVC) — remove what isn't essential

— Reassess vaccination status (pneumococcal, influenza, COVID, RSV) — sepsis recovery is a teachable moment

— Functional decline screen: many post-sepsis patients have cognitive/physical decline → PT/OT, home health

— Explain VRE colonization vs infection in lay terms

— Hand hygiene at home, especially before food prep and after toilet

— Notify all future healthcare providers of VRE history

— Avoid unnecessary antibiotics; ask "do I really need this?" for any future prescription

— Fatigue, cognitive impairment, PTSD, depression — screen at 1 and 3 months

— Refer to post-ICU clinic if available

During therapy monitoring:

Post-discharge follow-up cadence:

Long-term considerations:

Counseling points:

Post-sepsis syndrome:

Board pearl: Linezolid >2 weeks → check weekly CBC; >4 weeks → add ophthalmologic exam and neurologic exam for optic/peripheral neuropathy. Reversible if caught early; permanent if late.

CCS pearl: On CCS discharge, order "home health nursing," "ID clinic follow-up 1 week," "PICC line care education," "weekly CBC/CMP/CPK," and "primary care follow-up 2 weeks" — full discharge bundle scores higher than antibiotics alone.

Ethical, Legal, and Patient Safety Considerations

— Hand hygiene compliance is the single most modifiable factor; non-adherence is the most common root cause in VRE outbreak RCA

— Just culture framework: address system failures (gel dispensers, gown supply, staffing) rather than punitive blame

— Mandatory reporting to state health departments varies; VRE outbreaks must be reported per state regulations and HAI surveillance (NHSN)

— Joint Commission and CMS require formal stewardship programs in hospitals and nursing homes

— Inappropriate vancomycin use is a measurable quality metric

— PICC placement for OPAT: discuss line infection risk, thrombosis, malposition; document

— TEE: procedural risks (esophageal injury, sedation), alternatives, benefits

— Cardiac surgery for IE: high-risk consent including stroke, death, prolonged ICU

— Septic encephalopathy often impairs capacity → activate surrogate per state hierarchy

— Document capacity assessment each major decision

— Recurrent MDRO infections, LTAC-dependent, advanced age/frailty → palliative care consultation appropriate; recurrent VRE bacteremia carries high mortality

— Discuss DNR/DNI, comfort-focused care; avoid reflexive aggressive treatment when prognosis poor

— Communication failures between hospital → SNF/LTAC about VRE status, antibiotic plan, line care, and follow-up labs are the #1 source of OPAT complications and readmissions

— Use structured handoff (SBAR), confirm receiving facility can perform required monitoring (CPK, CBC), and ensure ID follow-up is booked before discharge

— Medication reconciliation including stop date for antibiotics — prevents both under- and over-treatment

— VRE status is PHI; share only with treating clinicians and facilities on need-to-know basis

— Avoid placing immunocompromised patient with VRE-colonized roommate; ethical duty of non-maleficence

Patient safety — infection control adherence:

Antibiotic stewardship as patient safety:

Informed consent edge cases:

Capacity and surrogate decision-making:

Goals-of-care:

Transition-of-care risks (Step 3 high yield):

Confidentiality:

Roommate/cohort issues:

Step 3 management: Before discharging a VRE bacteremia patient on OPAT to a SNF, (1) call the receiving facility, (2) confirm capacity to monitor weekly labs, (3) send written antibiotic plan with stop date, (4) book ID follow-up, (5) reconcile medications. This bundle prevents readmission and treatment failure.

High-Yield Associations and Rapid-Fire Clinical Facts

— Enterococcus = catalase-negative, gram-positive cocci in pairs/chains

— Grows in 6.5% NaCl and bile esculin, PYR-positive

— vanA gene → high-level resistance to vanco AND teicoplanin (inducible by either)

— vanB → vanco-R, teicoplanin-S

— vanC → intrinsic low-level vanco-R in E. gallinarum and E. casseliflavus (motile species)

— Daptomycin — pulmonary surfactant inactivates it; can't treat pneumonia

— Linezolid + SSRI → serotonin syndrome

— Linezolid + prolonged use → thrombocytopenia (weeks 2+), optic/peripheral neuropathy (>4 weeks), lactic acidosis

— Quinupristin-dalfopristin — myalgia/arthralgia, only E. faecium

— Tigecycline — black box for mortality, avoid in bacteremia

— Ampicillin — still works for ampicillin-S E. faecalis even when vanco-R

— Enterococcus = 3rd most common IE pathogen (after staph and viridans strep)

— E. faecalis IE → ampicillin + ceftriaxone × 6 weeks (avoid gentamicin nephrotoxicity)

— Liver transplant = highest-risk solid organ for VRE infection

— Asymptomatic VRE bacteriuria → don't treat (except pregnancy, pre-urologic procedure)

— Persistent bacteremia >72 h → TEE + reassess source + combination therapy

— Contact precautions, single room/cohort

— Alcohol hand rub WORKS for VRE (unlike C. difficile)

— Chlorhexidine bathing reduces ICU transmission

— No effective decolonization regimen

— Vancomycin, 3rd-gen cephalosporins, anti-anaerobics select for VRE

— Reducing these is the most impactful prevention

— Enterococcal bacteremia → TTE, then TEE if criteria

— E. gallolyticus IE → colonoscopy (colorectal CA); E. faecalis IE → consider colonoscopy

Microbiology pearls:

Antibiotic associations:

Clinical pearls:

Infection control:

Stewardship:

Tests/exam triggers:

Board pearl: Daptomycin + ceftaroline = salvage combo for persistent VRE bacteremia. Ampicillin + ceftriaxone = first-line for ampicillin-S E. faecalis IE. Linezolid = oral step-down option (100% bioavailable), but bacteriostatic — not preferred for IE or neutropenia.

Board Question Stem Patterns

— Stem 1: Hospitalized day 10 on pip-tazo for intra-abdominal abscess, now febrile with GPCs in chains, vanco-R E. faecium → answer: daptomycin 8–10 mg/kg IV q24h; remove or evaluate line; repeat blood cultures

— Stem 2: Liver transplant recipient with biliary leak, persistent fever despite pip-tazo, blood culture VRE → answer: daptomycin + source control (ERCP, drainage); ID consult

— Stem 3: Foley-catheterized nursing home patient, urine culture VRE, no symptoms, no fever → answer: do NOT treat; remove/replace catheter; document colonization

— Stem 4: VRE bacteremia, blood cultures still positive at 96 h on daptomycin 6 mg/kg → answer: increase daptomycin to 10–12 mg/kg, add ceftaroline or ampicillin, order TEE, reassess source control

— Stem 5: Patient on linezolid for VRE develops confusion, tremor, hyperreflexia, diaphoresis; home med list includes sertraline → answer: serotonin syndrome; stop linezolid, supportive care, cyproheptadine if severe

— Stem 6: Patient on daptomycin develops dyspnea, cough, bilateral infiltrates, peripheral eosinophilia after 3 weeks → answer: daptomycin-induced eosinophilic pneumonia; discontinue drug, start corticosteroids

— Stem 7: Pregnant woman, urine culture VRE (ampicillin-S E. faecalis), asymptomatic → answer: TREAT with ampicillin (asymptomatic bacteriuria treated in pregnancy)

— Stem 8: Infection control question — new VRE-positive admission, which precaution? → contact precautions, single room or cohort, gown/gloves, dedicated equipment

— Stem 9: Best long-term hospital strategy to reduce VRE → antibiotic stewardship (more than hand hygiene alone, more than environmental cleaning alone in tested options)

— Stem 10: Patient with E. faecalis (ampicillin-S, vanco-R) endocarditis → ampicillin 2 g q4h + ceftriaxone 2 g q12h × 6 weeks (NOT daptomycin first-line)

— Choosing vancomycin (ineffective)

— Choosing daptomycin for pneumonia (inactivated by surfactant)

— Treating asymptomatic bacteriuria in non-pregnant, non-pre-procedure patient

— Forgetting source control (line removal, abscess drainage)

— Missing TTE/TEE in enterococcal bacteremia

Classic Step 3 VRE stems:

Distractors to recognize:

Board pearl: When the stem mentions "culture growing gram-positive cocci in chains, vancomycin MIC >32" in a hospitalized patient on broad-spectrum antibiotics → answer almost always involves daptomycin (high dose) or linezolid + source control + contact precautions + ID consult.

One-Line Recap

VRE management hinges on confirming true infection (not colonization), choosing daptomycin (high-dose, 8–12 mg/kg) or linezolid based on syndrome and host, achieving source control (line removal, drainage), and implementing contact precautions plus antibiotic stewardship to prevent transmission and recurrence.

— E. faecium VRE → daptomycin 8–12 mg/kg or linezolid 600 mg q12h

— E. faecalis ampicillin-S (even if vanco-R) → ampicillin ± ceftriaxone

— Endocarditis → 6 weeks; bacteremia → 14 days from negative culture; cystitis → 5–7 days nitrofurantoin/fosfomycin

— Persistent bacteremia >72 h → escalate dose, add ceftaroline/ampicillin, repeat TEE, reassess source

— Remove infected central lines, drain abscesses, exchange biliary stents, extract infected hardware

— Replace long-dwell Foley before treating UTI; don't treat asymptomatic bacteriuria (except pregnancy/pre-urology)

— Contact precautions (gown + gloves), single room or cohort, dedicated equipment

— Hand hygiene with soap/water OR alcohol rub (alcohol works for VRE)

— Chlorhexidine bathing in ICU; no proven decolonization regimen

— Antibiotic stewardship is the highest-yield prevention — restrict vancomycin, 3rd-gen cephalosporins, anti-anaerobics

— Daptomycin → weekly CPK, avoid statins, watch for eosinophilic pneumonia

— Linezolid → weekly CBC, avoid serotonergic drugs, monitor for neuropathy >4 weeks

— Repeat blood cultures q48h until negative; TTE on all enterococcal bacteremia, TEE if criteria

— Structured handoff to SNF/LTAC/OPAT prevents readmission and treatment failure

Pharmacotherapy core:

Source control non-negotiables:

Infection control essentials:

Monitoring and transitions:

Board pearl: When in doubt on Step 3, the right VRE answer combines (1) correct drug, (2) source control, (3) repeat cultures, (4) ID consult, (5) contact precautions — pick the option that bundles these, not the one with just an antibiotic.